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surgeries. METHODS: This one-year retrospective cohort study was conducted at a
medical center in Taiwan from January 1st to December 31th in 2011. Adult patients
(above 18 years) who had undergone total hip replacement or total knee replace-
ment were identified by inpatient electronic database. Medical records were re-
viewed from the surgery day to at least three months post-operation for collecting
demographic details and DVT-related clinical symptoms as the surrogate of effec-
tiveness. Demographic and prescribing patterns of antithrombotics were assessed
by descriptive statistic. Relative risk (RR) was calculated with 95% confidence in-
terval (95%CI). RESULTS: Medical records of 212 patients (66.98% women) were
reviewed. A total of 81 patients (38.21%) received rivaroxaban, 37 patients (17.45 %)
received aspirin, 7 patients (3.30%) received warfarin, and 45 (21.22%) patients
received no antithrombotics and antiplatlets. There was no stroke case in aspirin,
warfarin, and aspirin/rivaroxaben combination group. Compared to other anti-
thrombotics, rivaroxaben was associated with higher RR for stroke (RR 1.11, 95%CI
0.10-11.92), but lower RR for bleeding (RR 0.83, 95%CI 0.32-2.19). However, aspirin/
rivaroxaben combination group showed an increase in bleeding events (RR 1.87,
95%CI 0.46-7.70). CONCLUSIONS: Treatment with aspirin or warfarin seems effec-
tively reduce the risk of stroke. Aspirin/rivaroxaben combination may increase
bleeding events. Further studies are needed to explore the effectiveness and safety
of antithrombotics using a longitudinal data source with sufficient patients’ char-
acteristic data.
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A MIXED TREATMENT COMPARISON (MTC) TO COMPARE THE EFFICACY OF
ANTI-THROMBOTIC AGENTS IN THE PREVENTION OF STROKE AND SYSTEMIC
EMBOLISM (SE) IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
(NVAF)
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This research was conducted during a review of the manufacturer’s submission
(MS) to the NICE Single Technology Appraisal programme for the oral direct factor
Xa inhibitor, rivaroxaban. OBJECTIVES: New anti-thrombotic drugs are available
for prevention of stroke in patients with NVAF but evidence on their clinical effec-
tiveness compared with existing treatments is limited. This research compared the
clinical effectiveness of rivaroxaban, dabigatran etexilate (dabigatran), aspirin and
adjusted standard dose warfarin (warfarin) in people with NVAF. METHODS: Ran-
domised controlled trials (RCTs) for inclusion were identified using the MS for
rivaroxaban, and 2 similar reports for dabigatran; inclusion was validated using
published systematic reviews. RCTs were assessed for comparability based on pa-
tient population, disease severity, and treatments received. A Bayesian MTC was
conducted, and fixed and random effects models were explored. Consistency was
assessed via pair-wise meta-analysis for each treatment versus warfarin. Odds
ratio (OR) was chosen as the summary statistic. RESULTS: The network of 8 RCTs
formed a “radiating star”. The fixed effects model was the best-fitting model. There
was reasonable agreement between the number of unconstrained data points,
residual deviance and pair-wise results, suggesting a coherent network. Statisti-
cally significant results compared with warfarin were: reduction in ischaemic
stroke with dabigatran (OR 0.78; 95% Credible Interval [95%CrI]: 0.60–1.00); reduc-
tion in SE with rivaroxaban (OR 0.24; 95%CrI: 0.07–0.54); reduction in minor ex-
tracranial bleeds with dabigatran (OR 0.88; 95%CrI: 0.82–0.96) and aspirin (OR 0.57;
95%CrI: 0.33–0.91); reduction in intracranial bleeds with dabigatran (OR 0.41;
95%CrI: 0.27–0.60) and rivaroxaban (OR 0.66; 95%CrI: 0.46–0.92); increase in myo-
cardial infarction with dabigatran (OR 1.43; 95%CrI: 1.02–1.97); and increase in dis-
continuations with dabigatran (OR 1.36; 95%CrI: 1.24–1.48). CONCLUSIONS: This
research suggests dabigatran and rivaroxaban may offer different clinical benefits
and harms in patients with NVAF compared with warfarin.
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OBJECTIVES: A 30-day rehospitalization rate for acute myocardial infarction (AMI)
following hospital discharge among patients with acute coronary syndrome (ACS)
who have received percutaneous coronary intervention (PCI) has been adopted as
a hospital quality and performance measure. This study sought to compare 30- and
90-day AMI-related rehospitalization rates between ACS-PCI patients receiving
clopidogrel versus those receiving prasugrel. METHODS: The study endpoint was
pre-specified, and analysis was done under blinding. Using a large geographically
diverse US database maintained by PREMIER, the study analyzed AMI-related re-
hospitalizations among ACS-PCI patients receiving either clopidogrel or prasugrel
between July 2009 and June 2011. Analysis included patients treated with prasugrel
who were on-label and clopidogrel-treated patients who would have been eligible
for prasugrel treatment per the label. Treatment differences in rehospitalization
rate at 30 and 90 days were analyzed. Unadjusted comparisons used chi-square
tests. Multivariate logistic regression analyses adjusted for baseline patient differ-
ences using propensity score stratification. RESULTS: Data were available for
83,576 patients, of which 74,163 received clopidogrel and 9,403 received prasugrel.
For clopidogrel and prasugrel, respectively, the observed AMI-related rehospital-
ization rates were 4.74% and 3.85% at 30 days (P0.0001) and 6.27% and 5.13% at 90
days (P0.0001). Prasugrel was associated with approximately 10% lower odds of
AMI-related rehospitalization (Odds ratio0.892 at 30 days [95% CI: 0.798-0.998];
Odds ratio0.901 at 90 days [95% CI: 0.817-0.994]). CONCLUSIONS: Compared to
clopidogrel-treated patients, prasugrel- treated patients experienced fewer rehos-
pitalizations for AMI at 30 days and 90 days following ACS-PCI discharge. Similar
results were obtained after adjusting for patient demographics and clinical char-
acteristics. The potential for unmeasured confounder bias is a limitation in this
real-world observational research.
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ASSOCIATION BETWEEN PERSISTENCE WITH STATINS AND REDUCTION OF
LOW DENSITY LIPOPROTEIN CHOLESTEROL: ANALYSIS OF REAL-LIFE DATA
FROM COMMUNITY SETTINGS
Shalev V, Goldstein I, Porath A, Chodick G
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OBJECTIVES: To quantify the association between persistence with statins and low
density lipoprotein cholesterol (LDL-C) levels using real-life data in community
settings.METHODS:A retrospective population-based cohort study was conducted
among eligible 87,219 primary-prevention and 15,139 secondary-prevention pa-
tients who are members of a large health maintenance organization and initiated
statins therapy between 1998 and 2008. Baseline and follow-up LDL levels were
collected from three months prior to the date of first dispensed statins (index date)
to six months afterwards. Persistence was assessed by proportion of follow-up
days covered (PDC) with statins. RESULTS: Over the study follow-up period, there
were significant (P 0.001) reductions in LDL-C levels of 54, 33 and 13 mg/dl among
highly persistent (PDC80%), poorly persistent (34%PDC80%), and non-per-
sistent statins users (PDC33%), respectively. In a multivariable model, high per-
sistence with statins therapy was associated with a 27% and 25% decrement in
LDL-C level among primary and secondary prevention cohorts, respectively. Sim-
ilarly, a higher proportion of the persistent statins users reached target LDL-C level
within the study follow-up period (80% and 58% among primary and secondary
prevention cohorts, compared to only 28% and 17%, among non-persistent
patients). CONCLUSIONS: In this observational population-based study, calculated
PDC with statins during study follow-up was strongly associated with drug effect of
LDL-C reduction. The results agree with previous estimates of statins efficacy from
randomized clinical trials, supporting the validity of using PDC methods as a mea-
sure of drug exposure.
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OBJECTIVES: Post-discharge thromboprophylaxis is the practice of prescribing an-
tithrombotic therapy for 21 days after discharge, commonly used in surgical pa-
tients who are at high risk for venothromboembolism (VTE). While randomized
controlled trials have demonstrated a risk reduction for VTE after major general
surgery, the incidence rate where it is cost effective has not been established.
Previous cost analyses have not included an effectiveness component, and have
not reported a threshold VTE incidence rate to help answer for which procedures it
should be implemented. This study sought to determine the VTE incidence thresh-
old for the cost-effectiveness of low molecular weight heparin for 4 weeks after
surgery as compared to inpatient prophylaxis only. METHODS: A cost-effective-
ness decision tree was created using TreeAge. Assigned probabilities were derived
from published literature. The decision point compared extended duration throm-
boprophylaxis with low molecular weight heparin for 21 days after discharge to
inpatient-prophylaxis alone, with base case assumptions based on an abdominal
oncologic resection without complications in a 45 year-old male. The end points
were pulmonary embolism or deep vein thrombosis with attendant costs and as-
signed effectiveness evaluated by QALY. Willingness to pay was set at $50,000/
QALY. Sensitivity analyses were performed to assess uncertainty within the model,
with particular interest in the threshold for cost-effectiveness based on VTE
incidence. RESULTS: Given base case assumptions with VTE probability of 4%,
extended duration thromboprophylaxis had an incremental cost effectiveness ra-
tio of $8123/QALY, which was considered cost-effective. The results were robust to
sensitivity analysis with the highest uncertainty associated with VTE incidence
and medication cost. The threshold for the relative cost-effectiveness was a VTE
incidence exceeding 2.53%. CONCLUSIONS: Given the base case assumptions, ex-
tended prophylaxis is more cost effective than inpatient prophylaxis alone, and the
threshold for its use should be cases where the estimated VTE risk exceeds 2.53%.
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FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH
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OBJECTIVES: Atrial fibrillation (AF) is associated with an increased stroke risk.
Anticoagulation with vitamin K antagonists (VKAs) such as warfarin has been the
recommended prophylactic strategy for AF patients but suffers from shortcomings,
including a need for regular monitoring. Novel oral anticoagulants (NOACs) were
developed with the advantages of absence of monitoring and improved effective-
ness and safety profiles. While clinical findings look promising, there are no direct
comparisons between these newer agents. Through indirect treatment compari-
sons (ITC), this study assessed the comparative effectiveness of dabigatran (110mg
and 150mg), rivaroxaban, apixaban, and warfarin in the prevention of thromboem-
bolic events among warfarin-eligible AF patients. METHODS: ITC models were
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